Sanofi (SAN.PA) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. SAN.PA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.69% | 30.00% | Pass |
| Interest-bearing investments | 9.09% | 30.00% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.40% | 33.00% | Pass |
| Interest-bearing investments | 6.68% | 33.00% | Pass |
| Non-liquid assets | 86.69% | at least 20.00% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.40% | 33.33% | Pass |
| Cash + interest-bearing securities | 6.68% | 33.33% | Pass |
| Accounts receivable | 13.31% | 33.33% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.40% | 33.33% | Pass |
| Cash + interest-bearing securities | 6.68% | 33.33% | Pass |
| Accounts receivable | 13.31% | 50.00% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.04% | 33.00% | Pass |
| Cash + interest-bearing securities | 8.07% | 33.00% | Pass |
| Accounts receivable | 8.02% | 33.00% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.97% | 33.00% | Pass |
| Cash + interest-bearing securities | 8.04% | 49.00% | Pass |
| Accounts receivable | 7.99% | 49.00% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 20.97% | 33.33% | Pass |
| Cash + interest-bearing securities | 8.04% | 33.33% | Pass |
| Accounts receivable | 16.03% | 49.00% | Pass |
| Non-permissible income | 0.71% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 37.40 | NEUTRAL |
| Stochastic %K (14) | 13.22 | BUY |
| CCI (20) | -182.51 | BUY |
| Williams %R (14) | -86.78 | BUY |
| MACD (12,26,9) | -0.40 | SELL |
| ROC (10) | -5.71 | SELL |
| Momentum (10) | -4.50 | SELL |
| EMA (10) | 76.13 | SELL |
| SMA (10) | 76.51 | SELL |
| EMA (20) | 76.47 | SELL |
| SMA (20) | 76.96 | SELL |
| EMA (30) | 76.46 | SELL |
| SMA (30) | 76.34 | SELL |
| EMA (50) | 76.30 | SELL |
| SMA (50) | 76.32 | SELL |
| EMA (100) | 76.15 | SELL |
| SMA (100) | 75.71 | SELL |
| EMA (200) | 76.81 | SELL |
| SMA (200) | 76.13 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - General
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2025-12-31, figures in EUR.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
